KKH Advisors

Congrats to all the companies named to the 2024 #Endpoints11 list today! ???? “We spent days debating dozens of finalists from around the globe. This year’s group of Endpoints 11 winners represents some of the biggest and most interesting bets happening in biotech,” said Endpoints News Executive Editor Drew Armstrong. The winners of the 2024 Endpoints 11 awards are: Lifordi Immunotherapeutics, Inc. Mirador Therapeutics Formation Bio Xaira Therapeutics MediLink Therapeutics Iambic Therapeutics Ascidian Therapeutics Capstan Therapeutics Seaport Therapeutics Metsera Cardurion Pharmaceuticals Read the full release: ????

We’re excited to announce today the world’s first human procedure of our graphene-based cortical interface in a patient undergoing brain tumor resection. ???? Our BCI tx technology is able to differentiate between healthy and cancerous brain tissue with micrometer-scale precision. The study was sponsored by the The University of Manchester and primarily funded by the European Commission’s Graphene Flagship project. Thank you to Chief Clinical Investigator Dr. David Coope, a neurosurgeon at the Manchester Centre for Clinical Neuroscience and Chief Scientific Investigator Kostas Kostarelos, Ph.D., Professor of Nanomedicine at The University of Manchester, the Catalan Institute of Nanoscience & Nanotechnology, and Co-Founder of INBRAIN. “The world’s first human application of a graphene-based BCI highlights the transformative impact of graphene-based neural technologies in medicine. This clinical milestone opens a new era for BCI technology, paving the way for advancements in both neural decoding and its application as a therapeutic intervention,” said Carolina Aguilar, CEO and Co-Founder of INBRAIN Neuroelectronics. Read the release: ???? https://lnkd.in/eYvtpvrV

WIRED reporter Emily Mullin speaks with our CEO Carolina Aguilar about the procedure today. ???? This morning, surgeons at The University of Manchester temporarily placed a thin, Scotch tape-like implant made of graphene on the patient’s cortex—the outermost layer of the brain. Made by Spanish company InBrain Neuroelectronics, the technology is a type of brain-computer interface, a device that collects and decodes brain signals. InBrain is among several companies, including Elon Musk’s Neuralink developing BCIs. “We are aiming to have a commercial product that can do #brain decoding and brain mapping and could be used in a variety of disorders,” says Carolina Aguilar, InBrain’s CEO and cofounder. Brain mapping is a technique used to help plan brain surgeries. When taking out a brain tumor, for instance, surgeons place electrodes on the brain to determine the location of motor and speech function in the brain so that they can safely remove the tumor without affecting the patient’s ability to move or speak. Read the article: https://lnkd.in/e_-MfkFe #neurotech #BCI #braincomputerinterface

Episode 86 of Cell & Gene: The Podcast is available! Ray Therapeutics, Inc.' Co-Founder and CEO, Paul Bresge joins me to discuss all things vision-restorative therapeutics. We talk through #optogenetics-based #genetherapies for #vision restoration and how the company’s optogenetics approach differs from other gene therapies on the market. Subscribe wherever you podcast to hear our informative discussion. #podcast #cellandgenetherapy #cgt #eyecare #biotech https://lnkd.in/eN3NBxdu

Venture mega-rounds are on the rise in biotechnology as the outlook for the industry brightens. Sixty-eight U.S. and European biotech startups raised venture financings of $100 million or more this year through Aug. 31, putting this year on track to at least approach the 106 mega-rounds closed in 2021, the highest number on record, according to Silicon Valley Bank. Venture capitalists are increasingly confident that biotech is stabilizing after two years in which valuations reset lower from their 2021 highs. Mega-rounds also reflect a flight to quality, as investors crowd around what they view as the strongest companies, some observers said. “If there is a migration to quality, I think it de-risks the industry,” said Dr. James H., managing partner of biotech investor Sofinnova Investments . “As an asset class, we should see better performance.” Article by Brian Gormley: https://lnkd.in/egPmqzab

We're excited to share that Koneksa will be presenting at the upcoming International Congress of Parkinson’s Disease and Movement Disorders. Join us on Sunday, September 29, from 13:00-15:00 in Exhibit Hall A as we present our poster on "Reliability of Digital Measures in Parkinson’s Disease and Their Implications for Sample Size Calculations" (Abstract #1237). Our EVP, Data Science Larsson Omberg and Principal Scientist, Jennie Lavine will be onsite. Come explore how #digital #biomarkers are shaping the future of Parkinson's research. More information: ???? https://lnkd.in/eApwb__C #MDSCongress #ParkinsonsResearch #DigitalHealth #ClinicalTrials

Our Co-founder, President and CTO Jared Tangney presented at the LSI Europe conference last week, and discussed what our team has been building at #biolinq. ???? For the past 10 years we’ve been at work to reimagine #biosensing from just below the surface of the skin and engineered a new category of #sensors that opens a world of possibilities to deliver new insights about your health. Learn more here: ???? https://www.biolinq.com/

We've all seen sci-fi movies where astronauts go into deep sleep for long space journeys, but how close are we to making that a reality? Astrophysicist & Hayden Planetarium director Neil deGrasse Tyson, Chuck Nice, and Gary O’Reilly team up with Ryan Sprenger Ph.D., Senior Research Scientist at Fauna Bio, to explore a question straight out of science fiction: can humans hibernate in space like animals do on Earth? ???? Ryan breaks down the science of #hibernation and torpor, explaining how animals like bears and ground squirrels lower their metabolic rates to survive harsh conditions. Learn how with the help of the NAIC grant, Ryan and Fauna Bio team Ashley Hermans, Tobias Niederwieser, Mark Boettger, and Adam Kohler, are creating the Space Torpor for Advanced Space Habitats (STASH) program, which aims to take steps towards making human hibernation a possibility for long-term space travel. Could unlocking the secrets of these animals help humans avoid muscle atrophy, radiation damage, and resource scarcity in #space? ?????? Watch the Startalks interview here: ???? https://lnkd.in/eh3VRXaP

We’re excited to announce the appointment of Rick Rutter, Ph.D., and Jorge Nieva, M.D., to our Board of Directors. The addition of these distinguished leaders in clinical development and manufacturing strengthens AffyImmune’s commitment to advancing its AIC100 program in advanced thyroid cancers and non-small cell lung cancer (NSCLC). “We are thrilled to welcome Rick and Jorge to our board at such an important time for AffyImmune, as we advance our CAR T cell product candidate AIC100 towards registrational studies for advanced thyroid cancers, and plan for our Phase 1 trial for non-small cell lung cancer,” said Daniel Janse, CEO, AffyImmune. “Their insight and counsel as members of our board will be invaluable as we validate a commercially robust CAR T cell manufacturing process and focus our NSCLC clinical strategy on patients that will receive the greatest benefit from AIC100.” Read the release: ???? https://lnkd.in/eDvVNE_m

We're back from Boston's #LSXUSA! ?? We had a blast seeing our CEO Ana Maiques join the "Strategic Synergies: Scaling Through Industry Collaboration" panel, explaining how we're harnessing the power of technology and #AI to advance #healthcare. Together with Kurt Haggstrom of Synchron, Anh Hoang Jana Care, Jonathan Hoyt of Olympus Corporation of the Americas, and JoJo Platt from Neurotech Reports moderating, they had a fascinating discussion about the challenges they face and possible partnerships to improve resilience and promote growth. She also had the chance to meet great minds like Carlos Castro Gonzalez, James Zanewicz, JD, LLM, RTTP, Amar Sawhney, Michael Bison, and many more! ?? Thanks to the team at LSX - partnering for Life Science eXecutives for organizing this wonderful event!